山东大学耳鼻喉眼学报 ›› 2022, Vol. 36 ›› Issue (4): 114-119.doi: 10.6040/j.issn.1673-3770.1.2021.152

• • 上一篇    

喉神经内分泌癌的研究进展

毛泽凡综述陈曦,程雷审校   

  1. 南京医科大学第一附属医院/江苏省人民医院 耳鼻咽喉科, 江苏 南京 210029;
  • 发布日期:2022-07-11
  • 通讯作者: 陈曦. E-mail:jsxycx@sina.com;程雷. E-mail: chenglei@jsph.org.cn
  • 基金资助:
    江苏高校优势学科建设工程(JX10231801)

Research advances in neuroendocrine carcinoma of the larynx

MAO ZefanOverview,CHEN Xi, CHENG LeiGuidance   

  1. Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu, China
  • Published:2022-07-11

PDF (PC)

293

摘要： 喉神经内分泌癌是一种罕见的起源于上皮型神经内分泌细胞的喉恶性肿瘤,根据分化程度和细胞类型分为4种组织学亚型:典型类癌、非典型类癌、小细胞神经内分泌癌和大细胞神经内分泌癌。不同肿瘤亚型差异很大,由于发病率过低致使这些差异的正确描述一直受到阻碍。因报道过少的病例或无法收集足够的样本量,文献中常常存在相互矛盾的结果,很难形成共同的认知。综述近期的文献资料,就喉神经内分泌癌的临床行为、特点、诊断、治疗及预后等方面进行文献复习,提高临床医生对该病的认识,优化诊治方案。

关键词: 喉肿瘤, 喉神经内分泌癌, 上皮型神经内分泌细胞, 小细胞神经内分泌癌, 大细胞神经内分泌癌

Abstract: Neuroendocrine carcinoma of the larynx is a rare malignant tumor of the larynx that originates from epithelial neuroendocrine cells. Based on the degree of differentiation and cell type, it can be divided into four histological subtypes: typical carcinoid, atypical carcinoid, small cell neuroendocrine carcinoma, and large cell neuroendocrine carcinoma. Despite the substantial differences across these subtypes, an accurate description of their differences has been impeded by the overly low incidence. A number of studies reported are frequently contradictory due to too few cases reported or the inability to collect a sufficient sample size, making it difficult to reach a consensus. This paper reviews the recent literature reports on the clinical behavior, characteristics, diagnosis, treatment, and prognosis of neuroendocrine carcinoma of the larynx, to provide an evidence for clinicians to broaden their understanding and optimize the diagnosis and treatment protocol for this disease.

Key words: Laryngeal neoplasm, Neuroendocrine carcinoma of the larynx, Epithelial neuroendocrine cells, Small cell neuroendocrine carcinoma, Large cell neuroendocrine carcinoma

中图分类号: 

  • R739.65
[1] Barnes L. Neuroendocrine tumours. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. Pathology and Genetics. Head and Neck Tumours. World Health Organization Classification of Tumours[M]. Lyon, France: IARC Press 2005: pp 135-139.
[2] Goldman NC, Hood CI, Singleton GT. Carcinoid of the larynx[J]. Arch Otolaryngol, 1969, 90(1): 64-67. doi:10.1001/archotol.1969.00770030066013.
[3] Wenig BM, Hyams VJ, Heffner DK. Moderately differentiated neuroendocrine carcinoma of the larynx. A clinicopathologic study of 54 cases[J]. Cancer, 1988, 62(12): 2658-2676. doi:10.1002/1097-0142(19881215)62: 12<2658: aid-cncr2820621235>3.0.co;2-m.
[4] Shanmugaratnam K. Histological Typing of Tumours of the Upper Respiratory Tract and Ear: World Health Organization International Histological Classification of Tumors 2nd ed. Berlin[M]. Germany: Springer-Verlag; 1991.
[5] Barnes L, Eveson JW, Reichart P, et al. Pathology and Genetics of Head and Neck Tumours: World Health Organization Classification of Tumors[M]. Lyon, France: IARC Press 2005.
[6] Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics Tumours of the Lung, Pleura, Thymus and Heart: World Health Organization Classification of Tumors[M]. Lyon, France: IARC Press; 2004.
[7] El-Naggar AK, Chan JKC, Takata T, et al. The fourth edition of the head and neck World Health Organization blue book: editors' perspectives[J]. Hum Pathol, 2017, 66: 10-12. doi:10.1016/j.humpath.2017.05.014.
[8] van der Laan TP, Plaat BE, van der Laan BF, et al. Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: A meta-analysis of 436 reported cases[J]. Head Neck, 2015,37(5):707-715. doi:10.1002/hed.23666.
[9] Strosberg C, Ferlito A, Triantafyllou A, et al. Update on neuroendocrine carcinomas of the larynx[J]. Am J Clin Pathol, 2019, 152(6): 686-700. doi:10.1093/ajcp/aqz106.
[10] Kumar PD, Simha N V, N S. Atypical carcinoid of larynx: a case study and a brief review[J]. J Clin Diagn Res, 2014, 8(4): KD03-KD04. doi:10.7860/jcdr/2013/7756.4294.
[11] Ferlito A, Rinaldo A. Primary and secondary small cell neuroendocrine carcinoma of the larynx: a review[J]. Head Neck, 2008, 30(4): 518-524. doi:10.1002/hed.20797.
[12] 房新志, 王振华, 柴敏秀. 喉大细胞神经内分泌癌[J]. 临床与实验病理学杂志, 2002, 18(6): 592-594. doi:10.13315/j.cnki.cjcep.2002.06.004. FANG Xinzhi, WANG Zhenhua, CHAI Minxiu. Large cell neuroendocrine carcinoma of larynx[J]. Chin J Clin Exp Pathol, 2002, 18(6): 592-594. doi:10.13315/j.cnki.cjcep.2002.06.004.
[13] 曹志星, 李东海, 赵甲升. 喉大细胞神经内分泌癌1例报道并文献复习[J]. 卫生职业教育, 2005, 23(8): 109-110. doi:CNKI:SUN:2DYX.O.2005-08-089.
[14] 周玉琳, 王轶. 喉大细胞神经内分泌癌1例[J]. 临床耳鼻咽喉头颈外科杂志, 2018,32(15): 1192-1193. doi:10.13201/j.issn.1001-1781.2018.15.016. ZHOU Yulin, WANG Yi. One case report of laryngeal large cell neuroendocrine carcinoma[J]. J Clin Otorhinolaryngol Head Neck Surg, 2018,32(15): 1192-1193. doi:10.13201/j.issn.1001-1781.2018.15.016.
[15] 侯丽, 高建中. 喉神经内分泌癌的诊断及治疗[J]. 宁夏医学杂志, 2008, 30(6): 527-528,480. HOU Li, GAO Jianzhong. Diagnosis and treatment of Laryngeal neuroendocrine carcinoma[J]. Ningxia Med J, 2008, 30(6): 527-528,480.
[16] 彭渝, 万锋, 邓彬华. 喉大细胞神经内分泌癌1例[J]. 武警后勤学院学报(医学版), 2012,21(3): 211-212,229. PENG Yu, WAN Feng, DENG Binhua. A case of large cell neuroendocrine carcinoma of larynx[J]. J Logist Univ CAPF Med Sci, 2012, 21(3): 211-212,229.
[17] 张洋, 段翰源, 李祖飞, 等. 25例喉神经内分泌癌的诊治与临床分析[J]. 肿瘤预防与治疗, 2019, 32(7): 607-611. doi:10.3969/j.issn.1674-0904.2019.07.009. ZHANG Yang, DUAN Hanyuan, LI Zufei, et al. Diagnosis, treatment and clinical analysis of 25 cases of laryngeal neuroendocrine carcinoma[J]. J Cancer Control Treat, 2019, 32(7): 607-611. doi:10.3969/j.issn.1674-0904.2019.07.009.
[18] Ferlito A, Devaney KO, Rinaldo A. Neuroendocrine neoplasms of the larynx: advances in identification, understanding, and management[J]. Oral Oncol, 2006, 42(8): 770-788. doi:10.1016/j.oraloncology.2006.01.002.
[19] 温晗光,陈缪安,林忠豪,等. 喉神经内分泌癌1例[J]. 山东大学耳鼻喉眼学报, 2011, 25(4): 73-74. doi:CNKI:SUN:SDYU.O.2014-04-030.
[20] Tian H, Chen Z, Wang C, et al. Hypopharyngeal paraganglioma with a paraneoplastic neurologic syndrome: a case report[J]. Head Neck, 2013, 35(10):E304-E307. doi:10.1002/hed.23164.
[21] Ghosh R, Dutta R, Dubal PM, et al. Laryngeal neuroendocrine carcinoma: a population-based analysis of incidence and survival[J]. Otolaryngol Head Neck Surg, 2015, 153(6): 966-972. doi:10.1177/0194599815594386.
[22] Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience[J]. Cancer, 2010, 116(9): 2166-2173. doi:10.1002/cncr.25033.
[23] D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer[J]. N Engl J Med,2007,356(19):1944-1956. doi:10.1056/NEJMoa065497.
[24] Lewis JS Jr, Westra WH, Thompson LD, et al. The sinonasal tract: another potential "hot spot" for carcinomas with transcriptionally-active human papillomavirus[J]. Head Neck Pathol,2014,8(3):241-249. doi:10.1007/s12105-013-0514-4.
[25] Bonilla-Velez J, Mroz EA, Hammon RJ, et al. Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: implications for treatment[J]. Otolaryngol Clin North Am,2013,46(4):521-543. doi:10.1016/j.otc.2013.04.009.
[26] Alos L, Hakim S, Larque AB, et al. p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas[J]. Virchows Arch. 2016, 469(3):277-284. doi:10.1007/s00428-016-1982-1.
[27] Jo VY, Krane JF, Pantanowitz L, et al. HPV-associated neuroendocrine carcinomas of the head and neck in FNA biopsies: Clinicopathologic features of a rare entity[J]. Cancer Cytopathol, 2019, 127(1): 26-34. doi:10.1002/cncy.22075.
[28] Halmos GB, van der Laan TP, van Hemel BM, et al. Is human papillomavirus involved in laryngeal neuroendocrine carcinoma?[J]. Eur Arch Otorhinolaryngol, 2013, 270(2): 719-725. doi:10.1007/s00405-012-2075-7.
[29] Clay V, Papaxoinis G, Sanderson B, et al. Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours[J]. Clin Transl Oncol, 2017, 19(5): 579-586. doi:10.1007/s12094-016-1568-z.
[30] Joseph MG, Shibani A, Panjwani N, et al. Usefulness of Ki-67, Mitoses, and Tumor Size for Predicting Metastasis in Carcinoid Tumors of the Lung: A Study of 48 Cases at a Tertiary Care Centre in Canada[J]. Lung Cancer Int,2015,2015:545601. doi:10.1155/2015/545601.
[31] 田智丹, 黄文斌. 基于不同的临床特点、总生存期和发病机制, 头颈部大细胞神经内分泌癌应与非典型类癌区分[J]. 临床与实验病理学杂志, 2012, 28(3): 347. doi:10.13315/j.cnki.cjcep.2012.03.047.
[32] Abiko Y, Ogawa I, Hattori Y, et al. Atypical carcinoid(neuroendocrine carcinoma)of the gingiva: counterpart of a laryngeal tumor[J]. Pathol Int,2004,54(2):97-100. doi:10.1111/j.1440-1827.2004.01598.x.
[33] Kusafuka K, Abe M, Iida Y, et al. Mucosal large cell neuroendocrine carcinoma of the head and neck regions in Japanese patients: a distinct clinicopathological entity[J]. J Clin Pathol, 2012, 65(8): 704-709. doi:10.1136/jclinpath-2012-200801.
[34] Alujevic A, Juric G, Separovic R, Kruslin B. Unusual features of metastatic atypical carcinoid of the larynx[J]. Eur Arch Otorhinolaryngol, 1998,255(6):318-321. doi:10.1007/s004050050068.
[35] Chung JH, Lee SS, Shim YS, et al. A study of moderately differentiated neuroendocrine carcinomas of the larynx and an examination of non-neoplastic larynx tissue for neuroendocrine cells[J]. Laryngoscope, 2004, 114(7): 1264-1270. doi:10.1097/00005537-200407000-00023.
[36] Hirsch MS, Faquin WC, Krane JF. Thyroid transcription factor-1, but not p53, is helpful in distinguishing moderately differentiated neuroendocrine carcinoma of the larynx from medullary carcinoma of the thyroid[J]. Mod Pathol, 2004, 17(6): 631-636. doi:10.1038/modpathol.3800105.
[37] Lewis JS Jr, Ferlito A, Gnepp DR, et al. Terminology and classification of neuroendocrine neoplasms of the larynx[J]. Laryngoscope, 2011, 121(6): 1187-1193. doi:10.1002/lary.21790.
[38] Pusceddu S, Lo Russo G, Macerelli M, et al. Diagnosis and management of typical and atypical lung carcinoids[J]. Crit Rev Oncol Hematol,2016,100:167-176. doi:10.1016/j.critrevonc.2016.02.009.
[39] Lewis JS Jr, Spence DC, Chiosea S, Barnes EL Jr, Brandwein-Gensler M, El-Mofty SK. Large cell neuroendocrine carcinoma of the larynx: definition of an entity[J]. Head Neck Pathol,2010,4(3):198-207. doi:10.1007/s12105-010-0188-0.
[40] Kusafuka K, Ferlito A, Lewis JS Jr, et al. Large cell neuroendocrine carcinoma of the head and neck[J]. Oral Oncol, 2012,48(3):211-215. doi:10.1016/j.oraloncology.2011.09.016.
[41] Ferlito A, Strojan P, Lewis JS Jr, et al.Large cell neuroendocrine carcinoma of the head and neck: a distinct clinicopathologic entity[J]. Eur Arch Otorhinolaryngol,2014,271(8):2093-2095. doi:10.1007/s00405-014-3090-7.
[42] McCluggage WG, Cameron CH, Arthur K, et al. Atypical carcinoid tumor of the larynx: an immunohistochemical, ultrastructural, and flow cytometric analysis[J]. Ultrastruct Pathol,1997,21(5):431-438. doi:10.3109/01913129709021942.
[43] Thompson ED, Stelow EB, Mills SE, et al. Large Cell Neuroendocrine Carcinoma of the Head and Neck: A Clinicopathologic Series of 10 Cases With an Emphasis on HPV Status[J]. Am J Surg Pathol,2016,40(4):471-478. doi:10.1097/PAS.0000000000000580.
[44] Ferlito A, Silver CE, Bradford CR, et al. Neuroendocrine neoplasms of the larynx: an overview[J]. Head Neck, 2009, 31(12): 1634-1646. doi:10.1002/hed.21162.
[45] Ferlito A, Lewis JS, Rinaldo A. The evolving management of laryngeal neuroendocrine carcinomas[J]. Eur Arch Otorhinolaryngol, 2011, 268(9): 1247-1248. doi:10.1007/s00405-011-1666-z.
[46] Singh S, Carnaghi C, Buzzoni R, et al. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary[J]. Neuroendocrinology,2018,106(3):211-220. doi:10.1159/000477585.
[47] Baugh RF, Wolf GT, Beals TF, et al. Small cell carcinoma of the larynx: results of therapy[J]. Laryngoscope, 1986, 96(11): 1283-1290. doi:10.1002/lary.1986.96.11.1283.
[48] Barker JL, Glisson BS, Garden AS, et al. Management of nonsinonasal neuroendocrine carcinomas of the head and neck[J]. Cancer, 2003, 98(11): 2322-2328. doi:10.1002/cncr.11795.
[49] Kalemkerian GP, Schneider BJ. Advances in small cell lung cancer[J]. Hematol Clin N Am, 2017, 31(1): 143-156. doi:10.1016/j.hoc.2016.08.005.
[50] Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer(CheckMate 032): a multicentre, open-label, phase 1/2 trial [J]. Lancet Oncol, 2016,17(7):883-895. doi:10.1016/S1470-2045(16)30098-5.
[51] Ott PA, Elez E, Hiret S, et al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study[J]. J Clin Oncol,2017,35(34):3823-3829. doi:10.1200/JCO.2017.72.5069.
[52] Lewis JS Jr, Ferlito A, Gnepp DR, et al. Terminology and classification of neuroendocrine neoplasms of the larynx[J]. Laryngoscope,2011,121(6):1187-1193. doi:10.1002/lary.21790.
[53] Deep NL, Ekbom DC, Hinni ML, et al. High-grade neuroendocrine carcinoma of the larynx: the mayo clinic experience[J]. Ann Otol Rhinol Laryngol, 2016, 125(6): 464-469. doi:10.1177/0003489415619179.
[54] Derks JL, van Suylen RJ, Thunnissen E, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?[J]. Eur Respir J,2017,49(6):1601838. doi:10.1183/13993003.01838-2016.
[55] Wang VE, Urisman A, Albacker L, et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden[J]. J Immunother Cancer,2017,5(1):75. doi:10.1186/s40425-017-0281-y.
[56] Aroldi F, Bertocchi P, Meriggi F, et al. Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung? A Case Report[J]. Case Rep Oncol,2014,7(2):478-483. doi:10.1159/000365413.
[1] 陈学军,高文,尹高菲,郭伟,黄俊伟,张洋. 鼻腔鼻窦神经内分泌癌8例并文献复习[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 77-82.
[2] 李晓明. 喉癌治疗中喉功能保留的历史、现状和未来[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 1-5.
[3] 刘鸣. 早期声门癌的内镜治疗[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 6-9.
[4] 黄若飞,陈立晓,陈歆维,於子卫,金斌,祝江才,董频. 喉异期喉重复癌[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 36-39.
[5] 孙笑晗,李娜. 喉保留策略在喉癌治疗中的应用—美国临床肿瘤学会临床实践指南更新(2017)介绍[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 40-42.
[6] 丁洁,孙彦. 142例喉癌术后患者整体睡眠质量状况调查分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 76-81.
[7] 张小平,杨登权,王少新,黄小明. 连续性院外管理对喉癌患者术后生活质量的影响[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 169-174.
[8] 陈慧君,宋圣花,周涵,董伟达,乔明哲,陈曦,徐进,林子萍,邢光前. 血小板与淋巴细胞比值对喉癌复发的预测价值[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 106-110.
[9] 冯剑,周涵,董伟达. 喉癌内镜诊断技术研究进展[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 129-133.
[10] 姚慧,万文锦. 同伴支持教育在全喉切除术后患者延续护理中的应用效果分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 138-142.
[11] 邹良玉,李连贺,岳文慧,韩志鹏,张子惠. MIF、GSK-3β在喉鳞状细胞癌中表达的临床意义及相关性研究[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 76-80.
[12] 陈立晓,蒋锐,於子卫. 窄带成像技术在咽喉肿瘤诊治中的应用[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 104-108.
[13] 陈红,曹慧玲,窦鑫,高下. 右侧鼻腔小细胞神经内分泌癌一例并文献复习[J]. 山东大学耳鼻喉眼学报, 2018, 32(1): 89-92.
[14] 张明德,张祖平,于学民,魏燕红,袁英. RASSF2A基因甲基化在喉癌组织中的表达及意义[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 64-67.
[15] 付玉贵,王海兰,孙德重,杨佩珍,陈彦林,陈志鹏. 保留部分环状软骨环的喉全切除术[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 73-75.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发